OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru
1. Date of occurrence of the event: Apr 20, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4
Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 Poster Number: 1220 / Abstract number: 1062 Title: Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998 Poster number: …
OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina
1. Date of occurrence of the event: Apr 7, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4. Taipei, Taiwan. April 06, 2021 …
OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland
1. Date of occurrence of the event: Mar 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
The Board of Directors resolved to hold 2021 Annual General Meeting
1. Date of the board of directors resolution: Mar 12, 2021 2. Date for convening the shareholders’ meeting: Jun 21, 2021 3. Location for convening the shareholders’ meeting: Masterlink Securities …
Announcement of not Distributing Dividends in 2020
1. Date of the board of directors resolution: Mar 12, 2021 2. Year or quarter which dividends belong to: Year of 2020 3. Period which dividends belong to: Jan 01, …
Announcement of 2020 Consolidated Financial Report
1. Date of the financial reports submitted to the board of directors or approved by the board of directors: Mar 12, 2021 2. Date of the financial reports approved by …
OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations of Mexico
1. Date of occurrence of the event: Mar 12, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.
1. Date of occurrence of the event: Feb 23, 2021 2. Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3. Relationship with the Company: None 4. Starting and ending …